Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Steve Nicholls Articles

PlayShould ACS patients start a PCSK9 inhibitor in hospital?

Should ACS patients start a PCSK9 inhibitor in hospital?

Guidelines recommend that very high-risk patients require combination lipid lowering therapy, ideally the combination of statin-ezetimibe and a PCSK9 inhibitor, to attain LDL cholesterol goal. The question is whether those with an acute coronary syndrome (ACS) should initiate a PCSK9 inhibitor with intensive statin therapy…

read more »
PlayAPOLLO trial with SLN360

APOLLO trial with SLN360

Professor Stephen Nicholls (Monash University, Australia) discusses the APOLLO trial with SLN360.  

read more »
PlayHuygens: Does PCSK9 inhibition impact the vulnerable plaque?

Huygens: Does PCSK9 inhibition impact the vulnerable plaque?

The HUYGENS study (High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study NCT03570697) investigated the impact of PCSK9 inhibition on the vulnerable plaque. Results were reported at ESC Congress 2021 (Virtual). Professor Stephen Nicholls, Monash University, Melbourne, Australia discusses the background to the…

read more »
PlayVIDEO: Prof Steve Nicholls discusses STRENGTH

VIDEO: Prof Steve Nicholls discusses STRENGTH

News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) puts the STRENGTH results in context

read more »
PlayVIDEO: Prof Steve Nicholls fish oils and AF

VIDEO: Prof Steve Nicholls fish oils and AF

News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) discusses fish oils and risk for atrial fibrillation and implications for clinical practice

read more »
Targeting PCSK9 inhibitors to the right patient

Targeting PCSK9 inhibitors to the right patient

Professor Stephen J Nicholls MBBS PhD, Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia  The clinical development of pharmacological inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) has received considerable attention by virtue of the expectation that these treatments would have the potential to…

read more »
Current status of IVUS studies of plaque burden: what next with GLAGOV?

Current status of IVUS studies of plaque burden: what next with GLAGOV?

Over the last decade, the use of serial intravascular ultrasound (IVUS) imaging has been critical for defining the relationship between achieved LDL cholesterol levels and atherosclerotic plaque burden. In this overview, Professor Steve Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia) discusses the…

read more »
PlayESC Congress 2015 buzz: Novel LDL lowering treatments

ESC Congress 2015 buzz: Novel LDL lowering treatments

Professor Steve Nicholls, University of Adelaide, Adelaide, Australia discusses the PCSK9 inhibitors versus CETP inhibitors

read more »
PlayPCSK9 therapeutics – the next story?

PCSK9 therapeutics – the next story?

Results from a Phase I trial of a new approach to PCSK9 therapeutics, small interfering RNA (siRNA) were presented at ESC Congress 2015. Professor Steve Nicholls, University of Adelaide, Adelaide, Australia discusses the findings and potential clinical implications of this strategy: what would be the…

read more »